Oral intake of Lactiplantibacillus pentosus LPG1 Produces a Beneficial Regulation of Gut Microbiota in Healthy Persons: A Randomised, Placebo-Controlled, Single-Blind Trial.

Nutrients. 2023;15(8)
Full text from:

Other resources

Plain language summary

Traditionally, fermented dairy products have dominated the probiotic food market. However, the demand for vegetable-based probiotic products is growing due to a shifting consumer preference for new alternatives, particularly among vegetarians and lactose-intolerant individuals. The aim of this study was to evaluate the influence of the oral administration of the potential probiotic from plant origin L. pentosus LPG1 on the bacterial gut microbiome in healthy volunteers. This study was a randomised, single-blind, single-centre, parallel study. Participants enrolled in the study were randomly assigned (1:1) to orally ingest LPG1 capsules or placebo capsules. There no significant differences between randomised groups in terms of baseline characteristics. Results post intervention showed that ingesting L. pentosus LPG1 modified the gut microbiota, increasing the presence of Parabacteroides and Agathobacter, and reducing Prevotella. Authors conclude that using plant-based probiotics to modulate gut microbiota is a promising strategy for enhancing gastrointestinal health in humans.


The search for vegetable-origin probiotic microorganisms is a recent area of interest. This study conducted a phase I clinical trial to assess the effects of oral administration of Lactiplantibacillus pentosus LPG1, a natural strain with probiotic potential isolated from table olive fermentations, on the gut microbiota. The trial was a randomised, placebo-controlled, single-blind study involving 39 healthy volunteers. Group A (n = 20) ingested one capsule/day of L. pentosus LPG1 containing 1 × 1010 UFC/capsule, while Group B (n = 19) received one capsule/day containing only dextrose (placebo). The capsules were taken during breakfast for 30 consecutive days. Human stool samples were collected from all volunteers at the beginning (baseline) and at the end of the study (post-intervention) and were subjected to 16S rRNA metataxonomic analysis using Illumina MiSeq. Sequencing data at the genus level were statistically analysed using traditional methods and compositional data analysis (CoDA). After treatment, the alpha diversity in Group B (placebo) decreased according to an increase in the Berger and Parker dominance index (p-value < 0.05); moreover, dominance D increased and Simpson 1-D index decreased (p-value < 0.10). The Lactobacillus genus in the faeces was included in the CoDA signature balances (selbal and coda4microbiome) and played a notable role in distinguishing samples from baseline and post-intervention in Group A (LPG1). Additionally, ingesting L. pentosus LPG1 modified the gut microbiota post-intervention, increasing the presence of Parabacteroides and Agathobacter, but reducing Prevotella. These findings suggest that L. pentosus LPG1 is a potentially beneficial gut microbiota modulator in healthy persons.

Lifestyle medicine

Fundamental Clinical Imbalances : Digestive, absorptive and microbiological
Patient Centred Factors : Mediators/Gut microbiota
Environmental Inputs : Nutrients ; Microorganisms
Personal Lifestyle Factors : Nutrition
Functional Laboratory Testing : Stool
Bioactive Substances : Probiotics

Methodological quality

Jadad score : 3
Allocation concealment : Yes


Nutrition Evidence keywords : Gut microbiota ; Probiotics